Overview

A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

Status:
Not yet recruiting

Trial end date:
2024-05-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb